Artivion (NYSE:AORT) EVP Sells $187,235.79 in Stock

Artivion, Inc. (NYSE:AORT) EVP Lance Berry sold 4,981 shares of the business’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $37.59, for a total transaction of $187,235.79. Following the transaction, the executive vice president owned 148,450 shares in the company, valued at $5,580,235.50. This trade represents a 3.25% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Artivion Trading Up 0.9%

Shares of AORT stock traded up $0.31 during trading hours on Wednesday, reaching $35.66. 300,261 shares of the stock were exchanged, compared to its average volume of 399,410. Artivion, Inc. has a 12-month low of $21.97 and a 12-month high of $48.25. The company’s 50-day moving average price is $42.51 and its 200-day moving average price is $43.14. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of 178.32 and a beta of 1.59. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. The firm had revenue of $118.30 million during the quarter, compared to analyst estimates of $116.42 million. Artivion had a return on equity of 7.43% and a net margin of 2.21%.Artivion’s quarterly revenue was up 19.2% compared to the same quarter last year. As a group, equities analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on AORT shares. Canaccord Genuity Group decreased their target price on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research report on Friday, February 13th. Needham & Company LLC restated a “buy” rating and issued a $58.00 price objective on shares of Artivion in a report on Monday, February 2nd. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Wall Street Zen downgraded shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Citizens Jmp upped their price target on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Artivion presently has an average rating of “Moderate Buy” and an average price target of $48.97.

Hedge Funds Weigh In On Artivion

Several hedge funds have recently modified their holdings of AORT. Squarepoint Ops LLC purchased a new position in Artivion in the 2nd quarter worth $664,000. Kennedy Capital Management LLC increased its holdings in shares of Artivion by 20.8% in the second quarter. Kennedy Capital Management LLC now owns 367,762 shares of the company’s stock valued at $11,437,000 after purchasing an additional 63,205 shares during the period. Oppenheimer Asset Management Inc. purchased a new position in shares of Artivion in the second quarter worth about $669,000. Sio Capital Management LLC lifted its holdings in shares of Artivion by 31.0% during the second quarter. Sio Capital Management LLC now owns 158,736 shares of the company’s stock worth $4,937,000 after purchasing an additional 37,558 shares during the period. Finally, Osterweis Capital Management Inc. purchased a new stake in Artivion in the second quarter valued at approximately $3,750,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.